Niraparib in Pancreatic Cancer

Pancreatic cancer patients with pathogenic variants in DNA repair genes may benefit from PARP inhibitor therapy, but efficacy beyond germline BRCA1/2 mutations remains uncertain. This multicenter phase II trial (NCT03601923) enrolled 32 patients with advanced pancreatic cancer harboring germline or somatic pathogenic variants in BRCA1, BRCA2, PALB2, ATM, or CHEK2 who had not progressed on prior platinum-based chemotherapy. Patients received niraparib 200-300 mg daily. Here we deposit the whole exome samples of six patients from the study (N=13 total samples). Patients P02, P03, P06, and P21 have matched tumor-normal blood pairs; patient P22 has a single tumor sample; and patient P30 has four tumor samples collected at different timepoints for longitudinal analysis.]]>
Inclusion Criteria: Advanced pancreatic cancer Documented germline or somatic pathogenic variant in at least one of the following genes: BRCA1, BRCA2, PALB2, ATM, or CHEK2 No prior disease progression on platinum-based chemotherapy Exclusion Criteria: Prior progression on platinum-based therapy Note: Only patients who consented to data sharing are included in this dbGaP submission (n=3 of 4 patients with whole exome sequencing data). ]]>